Tada T, et al. - In 567 patients with advanced hepatocellular carcinoma (HCC) who received sorafenib, researchers studied the impact of albumin–bilirubin (ALBI) grade compared to Child–Pugh classification on survival. Using time-dependent receiver operating characteristic analysis, the ability of ALBI and Child–Pugh scores to predict survival was also compared. In multivariate analyses, both Child–Pugh classification and ALBI grade were independently linked to overall survival. In patients with advanced HCC who received sorafenib therapy, the grade of ALBI is a better predictor of survival than the Child-Pugh classification.